Novartis AG (NOVN)

77.72
+1.03(+1.34%)
  • Volume:
    3,390,385
  • Bid/Ask:
    77.70/77.72
  • Day's Range:
    76.82 - 77.85
  • Type:Equity
  • Market:Switzerland
  • ISIN:CH0012005267
  • S/N:1200526

NOVN Overview

Prev. Close
76.69
Day's Range
76.82-77.85
Revenue
46.98B
Open
76.82
52 wk Range
70.42-86.91
EPS
3.65
Volume
3,390,385
Market Cap
173.84B
Dividend (Yield)
3.13
(3.91%)
Average Volume (3m)
3,300,643
P/E Ratio
20.95
Beta
1.17
1-Year Change
-2.42%
Shares Outstanding
2,236,739,037
Next Earnings Date
25 Oct 2021
What is your sentiment on Novartis AG?
or
Market is currently closed. Voting is open during market hours.

Novartis AG News

Novartis AG Analysis

Technical Summary

Type
5 Min
15 Min
Hourly
Daily
Monthly
Moving AveragesStrong BuyStrong BuyStrong BuyNeutralSell
Technical IndicatorsStrong BuyStrong BuyStrong BuyBuySell
SummaryStrong BuyStrong BuyStrong BuyNeutralSell

Novartis AG Company Profile

Novartis AG Company Profile

Industry
Major Drugs
Employees
109000

Novartis AG is a Switzerland-based pharmaceutical company. The Company develops, manufactures, and markets branded and generic prescription drugs, active pharmaceutical ingredients (APIs), biosimilars and ophthalmic products. The Company uses science and digital technologies for treatments in the disease areas of immunology, dermatology, cancer, ophthalmology, neuroscience, respiratory, cardiovascular, renal and metabolism. The business activities of the Company are divided into two segments: Innovative Medicines, which includes innovative patent-protected prescription medicines for blood pressure, cancer and other ailments, and Sandoz, which includes generic pharmaceuticals and biosimilars.

Read More
  • Hi Guys, I have been invested in Novartis for 5 years and have closely followed the pharmaceutical industry for years. I have been very disappointed with the returns and am looking to transfer my portfolio into riskier assets. Upon research, I think I may have found an even better pharmaceutical company going by the name of SpectrumX. SpectrumX are leaders in patented shielded HOCL formulations that have numerous applications in medical/pharma fields. They have also undergone 2 clinical trials for Covid-19 treatment (apparently not factored into the company valuation.) To me this company seems to be on track for high growth after the IPO, however I may be getting lost in the hype. Would love to hear people's thoughts on the stock as I am keen to invest early.
    0
    Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All CFDs (stocks, indexes, futures), cryptocurrencies, and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn't bear any responsibility for any trading losses you might incur as a result of using this data.
    Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.